Eli Lilly, Boehringer Ingelheim deal

Boehringer and Eli Lilly amended a 2011 deal to co-develop and co-commercialize a portfolio of diabetes candidates. Effective Jan. 2, 2015, the companies will exclusively commercialize their respectiv...